Osamu Ujikawa

This inventor holds 11 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 6 EPO patents. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2010-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Osamu Ujikawa. Retrieved from https://idiyas.com/inventor/osamu-ujikawa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 4)

% Patents Active = 63.6

CIPO Patents = 1

EPO Patents = 6 (Patent Applications = 7)

Average Co-Inventor Count = 3.9

ph-index = 4

Forward Citations = 65(Granted Patents)

Location History:

Osaka, JP (2010 - 2015)
Kanagawa, JP (2014 - 2022)

Company Filing History:

11 out of 1,226

Takeda Pharmaceutical Company Limited

patents

Years Active: 2010-2022

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11279713 - Heterocyclic compound and use thereof (2022-03-22),

2. 9527807 - Sulfonamide derivative and use thereof (2016-12-27),

3. 9499568 - Heterocyclic compound and use thereof (2016-11-22),

4. 9150591 - Heterocyclic compound and use thereof (2015-10-06),

5. 8957070 - Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity (2015-02-17),

6. 8937055 - Heterocyclic ring compound having muscle cell or adipocyte differentiation regulating action (2015-01-20),

7. 8778934 - Heterocyclic compound and use thereof (2014-07-15),

8. 8575154 - Heterocyclic compound and use thereof (2013-11-05),

9. 8410087 - Indole compound (2013-04-02),

10. 8349886 - Nitrogenated 5-membered heterocyclic compound (2013-01-08),

11. 7718798 - Indole compound (2010-05-18),

Sure, I can help you with that! Here is the article about inventor Osamu Ujikawa:

Title: Osamu Ujikawa: Pioneering Innovations in Pharmaceutical Sciences

Introduction:

Osamu Ujikawa, a visionary inventor based in Kanagawa, Japan, has made significant contributions to the field of pharmaceutical sciences. With a total of 11 patents to his name, Ujikawa's groundbreaking work has garnered recognition worldwide.

Latest Patents:

1. Heterocyclic compound and use thereof: Ujikawa's patented compound, with its AMPA receptor potentiating action, shows promise as a potential treatment for depression, schizophrenia, Alzheimer's disease, and ADHD.

2. Sulfonamide derivative and use thereof: Another one of Ujikawa's inventions, this compound enhances AMPA receptor function and holds potential as a therapeutic drug for various neurological disorders.

Career Highlights:

Osamu Ujikawa is affiliated with Takeda Pharmaceutical Company Limited, a renowned name in the pharmaceutical industry. His expertise and innovative approach have helped Takeda in its quest for developing cutting-edge medications.

Collaborations:

Ujikawa has collaborated with accomplished professionals in his field, including Masakuni Kori and Toshihiro Imaeda. Together, they have pushed the boundaries of pharmaceutical research and development.

Conclusion:

In conclusion, Osamu Ujikawa's relentless drive for innovation and his remarkable discoveries in the realm of pharmaceutical sciences underline his status as a trailblazer in the industry. His patents not only showcase his ingenuity but also signify his commitment to improving healthcare outcomes globally.

Profile summary based on public USPTO records.